Volume 16, Number 8—August 2010
CME ACTIVITY
Clostridium difficile Bacteremia, Taiwan1
Table 3
In vitro antimicrobial drug susceptibilities of 10 bacteremic Clostridium difficile isolates, Taiwan, 1989–2009*
| Antimicrobial agent | MIC, μg/mL |
Resistance breakpoint, μg/mL | No. (%) resistant isolates | ||
|---|---|---|---|---|---|
| Range | MIC50 | MIC90 | |||
| Vancomycin† | 0.5–1 | 0.5 | 1 | >2 | 0 |
| Metronidazole | 0.25–8 | 1 | 4 | >32 | 0 |
| Clindamycin | 0.03–>256 | 4 | >256 | >8 | 3 (30) |
| Penicillin | 0.25–8 | 4 | 4 | >2 | 9 (90) |
| Ampicillin/sulbactam | 0.5–8 | 2 | 4 | >32/16 | 0 |
| Cefmetazole | 0.25–32 | 16 | 32 | >64 | 0 |
| Meropenem | 0.12–2 | 1 | 2 | >16 | 0 |
| Imipenem | 0.12–16 | 8 | 16 | >16 | 4 (40) |
| Ertapenem | 0.06–16 | 8 | 8 | >16 | 0 |
| Doripenem | 0.12–8 | 4 | 4 | NA | NA |
| Daptomycin | 0.12–2 | 0.5 | 2 | NA | NA |
| Tigecycline | 0.03–0.12 | 0.03 | 0.06 | NA | NA |
| Fusidic acid | 1–8 | 1 | 2 | NA | NA |
*MIC50, 50% MIC; MIC90, 90% MIC, NA, not available.
†Vancomycin MIC breakpoint was recommended by the European Committee on Antimicrobial Susceptibility Testing (www.eucast.org); otherwise by the Clinical and Laboratory Standards Institute (22).
